Canakinumab in Schnitzler Syndrome

Seminars in Arthritis and Rheumatism

Volumn 42, Issue 4, 2013, Pages 413-416

  Vanderschueren, Steven ^a   Knockaert, Daniël ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Autoinflammatory; Canakinumab; Interleukin 1; Schnitzler syndrome

Indexed keywords

C REACTIVE PROTEIN; CANAKINUMAB;

ADULT; ARTHRALGIA; ARTICLE; CASE REPORT; CLINICAL TRIAL; DISEASE EXACERBATION; DRUG RESPONSE; DRUG TOLERABILITY; FATIGUE; FEVER; HUMAN; INJECTION SITE REACTION; LABORATORY TEST; MALE; PRIORITY JOURNAL; RASH; REMISSION; SCHNITZLER SYNDROME; SIDE EFFECT;

ADULT; ANTIBODIES, MONOCLONAL; HUMANS; INTERLEUKIN-1BETA; MALE; REMISSION INDUCTION; SCHNITZLER SYNDROME; TREATMENT OUTCOME;

EID: 84873703941     PISSN: 00490172     EISSN: 1532866X     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2012.06.003     Document Type: Article

References (12)

1. de Koning H.D., Bodar E.J., van der Meer J.W., Simon A. Schnitzler syndrome: Beyond the case reports: Review and follow-up of 94 patients with an emphasis on prognosis and treatment. Semin Arthritis Rheum 2007, 37:137-148. Schnitzler Syndrome Study Group.
2. Lipsker D. The Schnitzler syndrome. Orphanet J Rare Dis 2010, 5:38.
3. Gilson M., Abad S., Larroche C., Dhote R. Treatment of Schnitzler's syndrome with anakinra. Clin Exp Rheumatol 2007, 25:931.
4. Dybowski F., Sepp N., Bergerhausen H.J., Braun J. Successful use of anakinra to treat refractory Schnitzler's syndrome. Clin Exp Rheumatol 2008, 26:354-357.
5. Besada E., Nossent H. Dramatic response to IL1-RA treatment in longstanding multidrug resistant Schnitzler's syndrome: A case report and literature review. Clin Rheumatol 2010, 29:567-571.
6. Gasparyan A.Y., Ayvazyan L., Cocco G., Kitas G.D. Adverse cardiovascular effects of antirheumatic drugs: Implications for clinical practice and research. Curr Pharm Des 2012, 18:1543-1555.
7. Botsios C. Safety of tumour necrosis factor and interleukin-1 blocking agents in rheumatic diseases. Autoimmun Rev 2005, 4:162-170.
8. Dinarello C.A. Interleukin-1β and the autoinflammatory diseases. N Engl J Med 2009, 360:2467-2470.
9. Rigante D. The fresco of autoinflammatory diseases from the pediatric perspective. Autoimmun Rev 2012, 11:348-356.
10. Lachmann H.J., Kone-Paut I., Kuemmerle-Deschner J.B., Leslie K.S., Hachulla E., Quartier P., et al. Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med 2009, 360:2416-2425. Canakinumab in CAPS Study Group.
11. Krause K., Weller K., Stefaniak R., Wittkowski H., Altrichter S., Siebenhaar F., et al. Efficacy and safety of the interleukin-1 antagonist Rilonacept in Schnitzler syndrome: An open-label study. Allergy 2012, 67(7):943-950.
12. de Koning H.D., Schalkwijk J., van der Meer J.W., Simon A. Successful canakinumab treatment identifies IL-1β as a pivotal mediator in Schnitzler syndrome. J Allergy Clin Immunol 2011, 128:1352-1354.